The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's 2026 conference, its new interdisciplinary consensus guidelines, and the next steps for stuttering care. [WATCH TIME: 5 minutes]
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
The director of the Pediatric Neuromuscular Program at UCSF Benioff Children’s Hospital San Francisco discussed 2-year findings from the phase 2/3 VIBRANCE-MG study of nipocalimab in adolescents with generalized MG. [WATCH TIME: 6 minutes]
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
The professor of applied neuroimaging at the University of Edinburgh discusses how emerging genetic and vascular mechanisms are opening new therapeutic avenues beyond traditional risk factor management in cerebral small vessel disease. [WATCH TIME: 3 minutes]
The professor of applied neuroimaging at the University of Edinburgh discusses emerging imaging, blood-based, and functional biomarkers for tracking cerebral small vessel disease progression and evaluating treatment response. [WATCH TIME: 3 minutes]
At MSToronto 2026, investigators applied machine learning to health records, retinal scans, and blood samples to flag multiple sclerosis and neuromyelitis optica spectrum disorder years before diagnosis or disability worsening, and identified the symptoms and conditions that tend to come first.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.
At MSToronto 2026, researchers showed deep learning models that extract more from routine MRI scans than volume measures alone, and clinicians described uses beyond imaging, but speakers warned that most published MS models have never been tested outside the center that built them.
The editor-in-chief of the Journal of the American Heart Association discusses what editors prioritize in research manuscripts, common submission mistakes, and strategies for improving publication readiness. [WATCH TIME: 4 minutes]
Changes in health care use emerged 5 to 6 years before the first clinical manifestation of MS, with shifts in encounter patterns potentially reflecting underlying autoimmune activity and other disease-associated processes.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Terrie Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
A duo of neuroimmunology experts at Yale School of Medicine discussed new genetic and single-cell data linking Epstein-Barr virus persistence to multiple sclerosis risk genes. [WATCH TIME: 5 minutes]
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including improved lesion detection, imaging standardization, and the opportunities and challenges of AI. [WATCH TIME: 5 minutes]
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
